Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYZHXR)

• Drug Name: 4-(4-Methyl-indan-1-yl)-1H-imidazole Drug Info
• Synonyms: SCHEMBL7035172; CHEMBL102763; 1H-Imidazole, 5-(2,3-dihydro-4-methyl-1H-inden-1-yl)-; AKOS006291239; 4-(4-methylindan-1-yl)-1h-imidazole; 192208-31-4; L016358

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 9990325
  TTD Drug ID: DMYZHXR

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor alpha-2C (ADRA2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[2]
Dihydroergocristine	DM5SQ1G	Alcohol dependence	6C40.2	Approved	[3]
Brimonidine	DMQLT4N	Ocular hypertension	9C61.01	Approved	[4]
Amosulalol	DML8QSZ	Hypertension	BA00-BA04	Approved	[5]
Amezinium	DM6I2WQ	Hypotension	BA20-BA21	Approved	[6]
Propylhexedrine	DMTBW2O	Obesity	5B81	Approved	[7]
Tetrahydrozoline	DMT57WC	Ocular disease	1F00.1Z	Approved	[8]
Rilmenidine	DM13PQW	Hypertension	BA00-BA04	Approved	[9]
Xylometazoline	DMKV32D	Allergic rhinitis	CA08.0	Phase 4	[10]
TNX-102	DMO1234	Fibromyalgia	MG30.01	Phase 3	[11]

Drug(s) Targeting Adrenergic receptor alpha-2A (ADRA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lofexidine	DM1WXA6	Heroin and opiate withdrawal	6C43	Approved	[12]
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[2]
Connexyn	DMF29Q5	Attention deficit hyperactivity disorder	6A05.Z	Approved	[13]
Guanfacine	DMPN5IH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[14]
A295	DM55GO2	Aggressive cancer	2A00-2F9Z	IND submitted	[15]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[16]
DSP-1200	DM4WSHG	Depression	6A70-6A7Z	Phase 1	[17]
MAZAPERTINE	DMRHYAU	N. A.	N. A.	Discontinued in Phase 2	[18]
NMI-870	DMU596F	Sexual dysfunction	HA00-HA01	Discontinued in Phase 2	[19]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[20]

Drug(s) Targeting Adrenergic receptor alpha-1B (ADRA1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methamphetamine	DMPM4SK	Anxiety		Approved	[21]
Propericiazine	DME9JNL	Psychiatric disorder	6E8Z	Approved	[22]
Methoxamine	DMF5XQH	Hypertension	BA00-BA04	Approved	[23]
Phendimetrazine	DM6TS1N	Obesity	5B81	Approved	[24]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[16]
TIOSPIRONE	DME5QDP	N. A.	N. A.	Discontinued in Phase 3	[25]
Sunepitron	DM6M8ZX	N. A.	N. A.	Discontinued in Phase 3	[26]
MAZAPERTINE	DMRHYAU	N. A.	N. A.	Discontinued in Phase 2	[18]
SOU-001	DMPAEK5	Urinary incontinence	MF50.2	Discontinued in Phase 2	[27]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[28]

Drug(s) Targeting Adrenergic receptor alpha-2B (ADRA2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[2]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[16]
AGN-199981	DMP5Y1A	Neuropathic pain	8E43.0	Phase 2	[29]
INDORAMIN	DMNSJFD	Hypertension	BA00-BA04	Withdrawn from market	[30]
MAZAPERTINE	DMRHYAU	N. A.	N. A.	Discontinued in Phase 2	[18]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[20]
A-80426	DMBC3DG	N. A.	N. A.	Terminated	[31]
WB-4101	DMQU8B1	N. A.	N. A.	Terminated	[32]
SK&F-104078	DMRADBU	N. A.	N. A.	Terminated	[30]
(+/-)-nantenine	DM0L3GE	Discovery agent	N.A.	Investigative	[33]

Drug(s) Targeting Adrenergic receptor alpha-1D (ADRA1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxazosin	DM9PLRH	Benign prostatic hyperplasia	GA90	Approved	[34]
Armodafinil	DMGB035	Malignant glioma	2A00.0	Approved	[35]
Alfuzosin	DMZVMKF	Benign prostatic hyperplasia	GA90	Approved	[36]
Moxisylyte	DMFCLYW	Erectile dysfunction	HA01.1	Approved	[37]
Terazosin	DM3JCVS	Benign prostatic hyperplasia	GA90	Approved	[38]
Bunazosin	DM4I8O7	Glaucoma/ocular hypertension	9C61	Approved	[39]
Trimazosin	DM1QLST	Congestive heart failure	BD10	Approved	[40]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[16]
DL-017	DMM8GZT	Hypertension	BA00-BA04	Phase 1	[41]
PMID30124346-Compound-LDT8	DM5MUNG	Benign prostatic hyperplasia	GA90	Patented	[42]

Drug(s) Targeting Adrenergic receptor alpha-1A (ADRA1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SILODOSIN	DMJSBT6	Benign prostatic hyperplasia	GA90	Approved	[43]
NAFTOPIDIL	DMQ8R4E	Hypertension	BA00-BA04	Approved	[43]
Tamsulosin	DM5QF9V	Benign prostatic hyperplasia	GA90	Approved	[44]
Xatral	DMLHOA0	Benign prostatic hyperplasia	GA90	Approved	[45]
Dutasteride + tamsulosin	DM6P8HU	Benign prostatic hyperplasia	GA90	Phase 3	[46]
Besipirdine	DMLVNTA	Cognitive impairment	6D71	Phase 3	[47]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[16]
PMID30124346-Compound-LDT8	DM5MUNG	Benign prostatic hyperplasia	GA90	Patented	[42]
PMID30124346-Compound-LDT66	DMJMTNL	Benign prostatic hyperplasia	GA90	Patented	[42]
TIOSPIRONE	DME5QDP	N. A.	N. A.	Discontinued in Phase 3	[25]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-1A (ADRA1A)	TTNGILX	ADA1A_HUMAN	Inhibitor	[1]
Adrenergic receptor alpha-1B (ADRA1B)	TTBRKXS	ADA1B_HUMAN	Inhibitor	[1]
Adrenergic receptor alpha-1D (ADRA1D)	TT34BHT	ADA1D_HUMAN	Inhibitor	[1]
Adrenergic receptor alpha-2A (ADRA2A)	TTWG9A4	ADA2A_HUMAN	Inhibitor	[1]
Adrenergic receptor alpha-2B (ADRA2B)	TTWM4TY	ADA2B_HUMAN	Inhibitor	[1]
Adrenergic receptor alpha-2C (ADRA2C)	TT2NUT5	ADA2C_HUMAN	Inhibitor	[1]

References

• [1] Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potent... J Med Chem. 1997 Sep 12;40(19):3014-24.
• [2] Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
• [3] Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
• [5] Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
• [6] Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
• [7] Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
• [8] Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
• [9] Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
• [10] Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
• [11] Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
• [12] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [13] alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
• [14] Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023 Apr 7:1-13.
• [15] Clinical pipeline report, company report or official report of Klus Pharma
• [16] A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
• [19] Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
• [20] Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
• [21] Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9.
• [22] Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91.
• [23] Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2.
• [24] Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
• [25] 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
• [26] An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35.
• [27] Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83.
• [28] Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
• [29] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [30] Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
• [31] Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
• [32] alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
• [33] Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
• [34] The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
• [35] Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
• [36] Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
• [37] Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
• [38] Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
• [39] Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
• [40] The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
• [41] Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
• [42] 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
• [43] Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
• [44] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [45] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [46] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [47] Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.